Company / Cash & Equivalents
EXACT SCIENCES CORP Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$956.0M
FY2025
5-year range
$242.5M / $956.0M
FY2021-FY2025
Trend
+59.1%
vs FY2024
Sector context
#30 of 152
Health Care
What the data says
EXACT SCIENCES CORP's cash & equivalents of $956M is higher than 80% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $49M in FY2016 to $1.5B in FY2020.
Based on SEC 10-K filings.
$956M in FY2025 with a 5-year CAGR of -8.5%. Top quartile in the Health Care sector.
Improved from $605M to $956M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +58.0%
- 5-Year CAGR
- -8.5%
- 10-Year CAGR
- -
Sector benchmark
-18.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.5%, indicating a declining trend.
- In FY2025, cash & equivalents increased 59.1% year-over-year.
- Ranks #30 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $956.0M | +59.1% |
| FY2024 | $600.9M | -0.7% |
| FY2023 | $605.4M | +149.6% |
| FY2022 | $242.5M | -23.1% |
| FY2021 | $315.5M | -78.8% |
| FY2020 | $1.5B | +741.3% |
| FY2019 | $177.3M | +10.5% |
| FY2018 | $160.4M | +107.0% |
| FY2017 | $77.5M | +58.4% |
| FY2016 | $48.9M | +18.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026